[
  {
    "ts": null,
    "headline": "Elevance Health: The Potential Turnaround The Market Isn't Pricing In",
    "summary": "Elevance Health's recent FQ3 2025 results showed a double beat, with revenue up 12% year-over-year. Read why ELV stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=d4a757ed3f10e4df557cb1202eea43ad24a70c463485e918c3d8fbb4d6524372",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764629868,
      "headline": "Elevance Health: The Potential Turnaround The Market Isn't Pricing In",
      "id": 137657243,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1916997079/image_1916997079.jpg?io=getty-c-w1536",
      "related": "ELV",
      "source": "SeekingAlpha",
      "summary": "Elevance Health's recent FQ3 2025 results showed a double beat, with revenue up 12% year-over-year. Read why ELV stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=d4a757ed3f10e4df557cb1202eea43ad24a70c463485e918c3d8fbb4d6524372"
    }
  }
]